title: A phase II study of oxaliplatin in combination with doxorubicin as first-line systemic chemotherapy in patients with inoperable hepatocellular carcinoma.
abstract: OBJECTIVE
  We designed a phase II trial of the combination with oxaliplatin and doxorubicin for patients with unresectable HCC to evaluate the overall response rate (ORR) and the toxicity.
  
  
  METHODS
  Forty patients with inoperable, systemic chemotherapy naive HCC were enrolled. Finally, 32 patients received oxaliplatin (130 mg/m(2)) and doxorubicin (60 mg/m(2)) every 3 weeks.
  
  
  RESULTS
  Eighty-two treatment cycles were administered (median 2 cycles, range 1-6). There was no treatment-related mortality. The ORR was 15.6% (95% CI, 3.3-28.7) with five partial responses. The median overall survival and median overall progression free survival were 31 weeks (95% CI, 22-40 weeks) and 12 weeks (95% CI, 5-19 weeks). Nausea and peripheral neuropathy were most frequent non-hematologic toxicities (nausea, n = 15; peripheral neuropathy, n = 10). The most frequent grade 3-4 hematologic adverse event was neutropenia (14 of 82 cycles) including three cases of febrile neutropenia.
  
  
  CONCLUSIONS
  The combination of oxaliplatin and doxorubicin showed modest activity and a tolerable toxicity profile in advanced HCC patients.
authors: Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, 50 Irwon-dong, Gangnam-gu, Seoul, 135-710, South Korea.
authors: Ji Eun
authors: JE
authors: Uhm
authors: Joon Oh
authors: JO
authors: Park
authors: Jeeyun
authors: J
authors: Lee
authors: Young Suk
authors: YS
authors: Park
authors: Se Hoon
authors: SH
authors: Park
authors: Byung Chul
authors: BC
authors: Yoo
authors: Seung Woon
authors: SW
authors: Paik
authors: Kwang Cheol
authors: KC
authors: Koh
authors: Won Ki
authors: WK
authors: Kang
authors: Ho Yeong
authors: HY
authors: Lim
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D006528:Carcinoma, Hepatocellular / Q000188:drug therapy* / Q000556:secondary / Q000601:surgery; D004317:Doxorubicin / Q000008:administration & dosage; D005260:Female; D006801:Humans; D008113:Liver Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery; D008297:Male; D020714:Maximum Tolerated Dose; D008875:Middle Aged; D009367:Neoplasm Staging; D009944:Organoplatinum Compounds / Q000008:administration & dosage; D000077150:Oxaliplatin; D011379:Prognosis; D015996:Survival Rate; D016896:Treatment Outcome
chemical_list: D009944:Organoplatinum Compounds; D000077150:Oxaliplatin; D004317:Doxorubicin